Luminex
Streck Quality Controls for DiaSorin's Luminex Sepsis Tests Receive FDA Clearance
The quality controls are designed to verify the performance of the Luminex Verigene Blood Culture Gram-Positive and Gram-Negative tests.
Decline in DiaSorin's Q2 MDx Revenues Offset by Strength in Immunodiagnostics
Non-COVID-19 immunodiagnostics revenues drove an otherwise strong quarter for DiaSorin with continued growth in North America and Europe and slow improvement in China.
DiaSorin Q1 Revenues Fall 19 Percent on COVID Sales Decline
A 78 percent decline in COVID testing revenues was partially offset by revenue growth in its other diagnostics businesses.
DiaSorin 2022 Revenues Grow 10 Percent
For 2023, total revenues are expected to decline 14 percent year over year, and COVID-19 revenues are expected to be down 75 percent to €60 million.
DiaSorin Gets FDA 510(k) for Molecular COVID-19/Flu Assay
The real-time RT-PCR Simplexa COVID-19 & Flu A/B Direct assay is designed for use on the company's Liaison MDX instrument, with results in about one hour.
Sep 9, 2022
Jul 9, 2021
Apr 13, 2021